Cerapedics Announces Canadian Approval of its next-generation bone graft
Canada will be the first commercial market to launch i-FACTOR®+ Matrix
Find out moreCerapedics Announces FDA approval of an IDE supplement
The IDE Supplement allows for a reduction in the total number of patients required to be enrolled in the ASPIRE IDE Study on P15-L bone graft in the lumbar spine.
Find out moreCerapedics Announces Results from Clinical Trial of i-FACTOR® Peptide Enhanced Bone Graft in Lumbar Fusion Surgery
Data published in The Spine Journal show elderly patients undergoing non-instrumented fusion achieve statistically significantly higher fusion rate with i-FACTOR bone graft compared to allograft
Find out moreCerapedics Announces FDA Approval of PMA Supplement Based on Two-Year Clinical Data
i-FACTOR® Peptide Enhanced Bone Graft continues to demonstrate statistical superiority to autologous bone in cervical spine surgery
Find out moreCerapedics Announces Expansion of Colorado Headquarters
Ortho-biologics company adds 10,000 square feet and doubles employee headcount at Denver metropolitan headquarters
Find out moreNew V.P. of Clinical and Market Development
Cerapedics Appoints Patrick O’Connor as Vice President of Clinical and Market Development
Find out moreCerapedics announces ISASS bone grafting policy statement
Society states company's drug-device combination technology shown to be safe and effective as autograft replacement with compelling clinical evidence .
Find out moreCerapedics named company of the year
MedTech Outlook’s Top 10 Orthopedic Solution Providers.
Find out moreCerapedics named as a finalist for company of the year
The finalists are in for the 10th annual PM360 Trailblazer Awards. PM360, a leading health-marketing industry trade magazine, will honor the pharmaceutical and medical device industries’ most influential innovators.
Find out moreCerapedics announces first patients enrolled in IDE Clinical Trial of P-15L Bone Graft for transforaminal lumbar interbody fusion surgery
Proprietary synthetic small peptide technology (P-15) is being evaluated in patients across the U.S. with degenerative disk disease
Find out more
Welcome to Cerapedics
Choose your region
